MedTrace Logo

Salbutamol Tolerance Onset

NCT01338311 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2012-07-20

No results posted yet for this study

Summary

Overuse of inhaled bronchodilator beta agonist medication results in a loss of effectiveness (i.e. tolerance). This has been shown for the short acting beta agonist salbutamol and the long acting beta agonist salmeterol. Tolerance to salmeterol is present within 24 hours. The onset of tolerance to salbutamol is not known.

Conditions

Interventions

DRUG

salbutamol

200mcg twice daily for a total of 7 doses

DRUG

Placebo

200mcg twice a day for a total of 7 doses (3.5 days).

Sponsors & Collaborators

  • University of Saskatchewan

    lead OTHER

Principal Investigators

  • Donald W Cockcroft, MD · University of Saskatchewan

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01338311 on ClinicalTrials.gov